Published in Eur Arch Otorhinolaryngol on December 25, 2009
Total thyroidectomy as the single surgical option for benign and malignant thyroid disease: a surgical challenge. Arch Med Sci (2013) 1.04
Disparity in the management of Graves' disease observed at an urban county hospital: a decade-long experience. Am J Surg (2012) 0.88
[Graves' ophthalmopathy from the internist's perspective]. Ophthalmologe (2011) 0.76
Alternating from subtotal thyroid resection to total thyroidectomy in the treatment of Graves' disease prevents recurrences but increases the frequency of permanent hypoparathyroidism. Langenbecks Arch Surg (2011) 0.75
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med (1998) 3.98
Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med (1992) 3.86
Graves' disease. N Engl J Med (2000) 3.50
Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab (2006) 1.92
Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) (2008) 1.85
Thyroidectomy remains an effective treatment option for Graves' disease. Am J Surg (2006) 1.67
The efficacy of thyroidectomy for Graves' disease: A meta-analysis. J Surg Res (2000) 1.45
Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab (1996) 1.40
Outcome of differentiated thyroid cancer in Graves' patients. J Clin Endocrinol Metab (1998) 1.23
Surgery for Graves' disease: total versus subtotal thyroidectomy-results of a prospective randomized trial. World J Surg (2000) 1.19
Surgical treatment of Graves' disease: subtotal or total thyroidectomy? Surgery (1996) 1.17
Total thyroidectomy replaces subtotal thyroidectomy as the preferred surgical treatment for Graves' disease. ANZ J Surg (2005) 1.17
Surgical treatment of Graves' disease: evidence-based approach. World J Surg (2008) 1.15
Total thyroidectomy is now the preferred option for the surgical management of Graves' disease. ANZ J Surg (2002) 1.13
Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid (2005) 1.10
Surgical treatment of hyperthyroidism: a ten-year experience. Thyroid (2001) 0.96
The effect of preoperative Lugol's iodine on thyroid blood flow in patients with Graves' hyperthyroidism. Surgery (1987) 0.94
Hyperthyroidism: diagnosis and treatment. Am Fam Physician (2005) 0.89
Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol (2001) 0.86
Surgical management of Graves' disease -10-year prospective trial at a single institution. Endocr J (2008) 0.86
Papillary thyroid carcinoma. Etiology, assessment, and therapy. Endocrinol Metab Clin North Am (1995) 0.84
The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey. Acta Endocrinol Suppl (Copenh) (1987) 0.82
Safety and efficacy of surgical management of hyperthyroidism: 15-year experience from a tertiary care center in a developing country. World J Surg (2007) 0.82
Treatment of hyperthyroidism with radioactive iodine. Endocrinol Metab Clin North Am (1998) 0.81
Total thyroidectomy for the treatment of hyperthyroidism in patients with ophthalmopathy. Thyroid (2002) 0.81
Technic of subtotal thyroidectomy. Surg Clin North Am (1949) 0.75
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res (2008) 5.88
Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27
Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2007) 4.66
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol (2008) 3.23
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18
The role of thyroid autoimmunity in fertility and pregnancy. Nat Clin Pract Endocrinol Metab (2008) 2.06
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 2.01
DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med (2011) 1.81
HER2-positive circulating tumor cells in breast cancer. PLoS One (2011) 1.73
Thyroid autoimmunity and hypothyroidism before and during pregnancy. Hum Reprod Update (2003) 1.57
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res (2002) 1.53
Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol (2011) 1.52
Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res (2007) 1.50
Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. Clin Breast Cancer (2004) 1.46
The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch (2010) 1.44
Selective neck dissection in the management of the neck after (chemo)radiotherapy for advanced head and neck cancer. Proposal for a classification update. Head Neck (2010) 1.42
Thyroid disease and female reproduction. Clin Endocrinol (Oxf) (2007) 1.35
Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck (2006) 1.23
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther (2004) 1.17
Thyroid autoimmunity and the risk of miscarriage. Best Pract Res Clin Endocrinol Metab (2004) 1.15
Parathyroid carcinoma: a review with three illustrative cases. J Cancer (2011) 1.14
Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res (2005) 1.13
Assisted reproduction and thyroid autoimmunity: an unfortunate combination? J Clin Endocrinol Metab (2003) 1.11
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer (2002) 1.11
Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid (2008) 1.10
Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics (2009) 1.05
Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. Clin Cancer Res (2012) 1.03
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther (2006) 1.03
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res (2008) 1.02
Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast Cancer Res Treat (2007) 1.02
Processed pseudogenes acquired somatically during cancer development. Nat Commun (2014) 1.00
Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol (2012) 1.00
mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. PLoS One (2012) 0.99
Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proc Natl Acad Sci U S A (2005) 0.98
Thyroid dysfunction and autoimmunity in infertile women. Thyroid (2002) 0.98
Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol (2009) 0.97
Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. Int J Cancer (2006) 0.97
Bringing molecular prognosis and prediction to the clinic. Clin Breast Cancer (2005) 0.95
Thyroid function inside and outside of pregnancy: what do we know and what don't we know? Thyroid (2005) 0.95
Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res Treat (2008) 0.95
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer (2007) 0.94
High prevalence of thyroid disorders in pregnant women in a mildly iodine-deficient country: a population-based study. J Clin Endocrinol Metab (2013) 0.94
Impact of ovarian hyperstimulation on thyroid function in women with and without thyroid autoimmunity. J Clin Endocrinol Metab (2004) 0.93
High-risk human papillomavirus infection in HIV-positive African women living in Europe. J Int AIDS Soc (2013) 0.91
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res (2012) 0.90
Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? Eur J Cancer (2008) 0.90
Miscarriage in women with positive anti-TPO antibodies: is thyroxine the answer? J Clin Endocrinol Metab (2006) 0.89
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology. BMC Genomics (2014) 0.88
Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. Int J Clin Oncol (2002) 0.88
Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). PLoS One (2010) 0.85
Association of duoxes with thyroid peroxidase and its regulation in thyrocytes. J Clin Endocrinol Metab (2009) 0.85
Thyroid function after assisted reproductive technology in women free of thyroid disease. Fertil Steril (2005) 0.85
Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expression. Exp Cell Res (2007) 0.85
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. Semin Oncol (2005) 0.84
Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women. J Infect Dis (2013) 0.84
Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. Clin Nucl Med (2008) 0.83
A therapeutic approach to perianal extramammary Paget's disease: topical imiquimod can be useful to prevent or defer surgery. Med Sci Monit (2007) 0.83
Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis. PLoS One (2013) 0.83
Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat (2002) 0.83
Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): new tools for ductal carcinoma in situ (DCIS). Breast J (2011) 0.82
Seasons but not ethnicity influence urinary iodine concentrations in Belgian adults. Eur J Nutr (2010) 0.82
Pathology as the cornerstone of human tissue banking: European consensus expert group report. Biopreserv Biobank (2009) 0.81
Impact of the ovarian hyperstimulation syndrome on thyroid function. Thyroid (2008) 0.80
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. Radiother Oncol (2012) 0.80
Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer. PLoS One (2013) 0.80
Lymphoscintigraphy in angiomyomatous hamartomas and primary lower limb lymphedema. Clin Nucl Med (2009) 0.80
Iodine nutrition requirements during pregnancy. Thyroid (2006) 0.80
Infrared imaging in breast cancer: automated tissue component recognition and spectral characterization of breast cancer cells as well as the tumor microenvironment. Analyst (2014) 0.79
Role of Epac and protein kinase A in thyrotropin-induced gene expression in primary thyrocytes. Exp Cell Res (2012) 0.79
Increased TBG during pregnancy and increased hormonal requirements. Thyroid (2004) 0.79
Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy. Urol Int (2011) 0.78
Gene expression in thyroid autonomous adenomas provides insight into their physiopathology. Oncogene (2005) 0.78
Molecular characterization of breast cancer cell lines by a low-density microarray. Int J Oncol (2005) 0.78
5-aza-2'-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro. Thyroid (2013) 0.77
Follow-up strategies in head and neck cancer other than upper aerodigestive tract squamous cell carcinoma. Eur Arch Otorhinolaryngol (2012) 0.76
Marginal zone B-cell lymphoma of the sinonasal tract in an eleven-year-old girl. Med Pediatr Oncol (2003) 0.76
Peptides targeting estrogen receptor alpha-potential applications for breast cancer treatment. Curr Pharm Des (2011) 0.76
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. Future Oncol (2013) 0.75
Gestational hypothyroxinemia and the beneficial effects of early dietary iodine fortification. Thyroid (2009) 0.75
Eighteen months clinical experience with the GeneSearch breast lymph node assay. Am J Surg (2009) 0.75
Personal considerations on the 2011 American Thyroid Association and the 2007 Endocrine Society pregnancy and thyroid disease guidelines. Thyroid (2011) 0.75
Inflammatory Stroma of Lymphoepithelioma-like Carcinoma of the Cervix: Immunohistochemical Study of 3 Cases and Review of the Literature. Int J Gynecol Pathol (2017) 0.75
The Belgian experience with the cyranose heat moisture exchange filter. A multicentric pilot study of 12 total laryngectomees. Eur Arch Otorhinolaryngol (2003) 0.75
Acute increase in goiter size during a normal pregnancy: an exceptional case report. Thyroid (2003) 0.75
Does clinical and radiological response predict complete tumor control in N2-N3 squamous cell head and neck cancer after non-operative management of the neck? Acta Otolaryngol (2006) 0.75
Decrease of estrogen receptor expression and associated ERE-dependent transcription in MCF-7 breast cancer cells after oligomycin treatment. Steroids (2003) 0.75